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Objectives: The recommended zolpidem starting dose was lowered in females (5 mg
vs. 10 mg) since side effects were more frequent and severe than those of males;
the mechanism underlying sex differences in pharmacokinetics (PK) is unknown. We
hypothesized that such differences were caused by known sex-related variability in
alcohol dehydrogenase (ADH) expression.
Methods: Male, female, and castrated male rats were administered 2.6 mg/kg
zolpidem, ± disulfiram (ADH/ALDH pathway inhibitor) to compare PK changes induced
by sex and gonadal hormones. PK analyses were conducted in rat plasma and rat brain.
Key findings: Sex differences in PK were evident: females had a higher CMAX (112.4
vs. 68.1 ug/L) and AUC (537.8 vs. 231.8 h∗ug/L) than uncastrated males. Castration
induced an earlier TMAX (0.25 vs. 1 h), greater CMAX (109.1 vs. 68.1 ug/L), and a
corresponding AUC increase (339.7 vs. 231.8 h∗ug/L). Administration of disulfiram
caused more drastic CMAX and TMAX changes in male vs. female rats that mirrored
the effects of castration on first-pass metabolism, suggesting that the observed PK
differences may be caused by ADH/ALDH expression. Brain concentrations paralleled
plasma concentrations.
Conclusion: These findings indicate that sex differences in zolpidem PK are influenced
by variation in the expression of ADH/ALDH due to gonadal androgens.
Keywords: zolpidem, drug metabolism, pharmacokinetics, testosterone
INTRODUCTION
Zolpidem is a gamma-aminobutyric acid (GABA) agonist that is indicated for the treatment
of insomnia characterized by difficulties with sleep initiation. Sex-specific differences in
pharmacokinetics (PK) have been observed in which females have greater exposure than males
and have increased probabilities of experiencing undesired, persistent pharmacological effect after
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waking (typically drowsiness) (Greenblatt et al., 2000, 2014a;
Verster et al., 2014). To address sex-related adverse events, the
FDA reduced the recommended initial dose by half in females
(Food and Drug Administration [FDA], 2008).
Zolpidem is hydroxylated by CYP3A4, rapidly oxidized to
an aldehyde by alcohol dehydrogenases (ADHs), and finally
converted into a carboxylic acid by aldehyde dehydrogenases
(ALDHs). The major circulating metabolite is zolpidem phenyl
4-carboxylic acid (ZPCA; 72–86%), with zolpidem 6-carboxylic
acid (ZCA) making up roughly ∼10% of the administered dose
(Gillet, 1991; Pichard et al., 1995). It is currently unknown
which ADH/ALDH enzyme classes are responsible for the
metabolism of zolpidem, and whether gastric ADH/ALDH
pathways contribute to zolpidem disposition. Nevertheless, along
with certain cytochromes P450, such as CYP3A that acts
synergistically with other enzymes in the gastric mucosa of
humans and animals (Yoon et al., 2011), the ADH/ALDH
enzyme pathway is likely the major contributor to the
bioavailability and elimination of zolpidem.
CYP3A4 activity is greater in females and is therefore unlikely
to result in slower metabolism in women (Wolbold et al., 2003).
However, it is well known that ADH/ALDH expression in the
gastrointestinal (GI) tract is much lower in females vs. males,
likely due to differences in androgens (Table 1). Low ADH
activity would be expected to slow CYP3A4 zolpidem metabolism
due to inefficient removal of the products of CYP3A4-mediated
zolpidem metabolism, based on Le Chatelier’s principle. Sex
hormone concentration differences are also responsible for
variability in ADH expression in aging, which is consistent with
the observed reduction in zolpidem clearance in older individuals
(Greenblatt et al., 2014b). Similar sexual- and age-dimorphic Adh
expression profiles have also been observed in the GI tracts and
livers of rats (Estonius et al., 1993; Aasmoe and Aarbakke, 1999;
Westerlund et al., 2007).
ADH expression is greatest in the liver while smaller amounts
have been observed in the GI tract and the kidney (Estonius
et al., 1993; Aasmoe and Aarbakke, 1999; Westerlund et al.,
2007). The ALDH inhibitor, disulfiram, slows ADH metabolism
TABLE 1 | Alcohol dehydrogenase (Adh) Class 1-V and Aldh isozymes in humans and rats.
Enzyme class Isozymes in
humans
Human
expression sites
Rat expression sites Sexually dimorphic
expression M vs. F
Metabolic
parameter
Reference
ADH Ethanol
Km (mM),
Vmax (min−1)
Class I ADH1A ADH1B∗1,
ADHB∗2,
ADH1B∗3,
ADH1C∗1,
ADH1C∗2
Liver (all) and
stomach
(ADH1C∗1)
Duodenum, colon,
rectum, liver, kidney,
stomach, greatest
expression in the above
tissues vs. other ADH
classes.
Higher in female rats’
liver
Lower in female rats’
gastrointestinal tract
4.0, 30
0.05, 4
0.9, 350
40.0, 300
1.0, 90
0.6, 40
Estonius et al., 1993;
Aasmoe and Aarbakke,
1999; Westerlund et al., 2007
ADH2 ADH4 Liver Liver, kidney, stomach,
duodenum
Lower in female rats’
liver
30, 20 Estonius et al., 1993;
Aasmoe and Aarbakke, 1999
ADH3 ADH5 Most tissues Tongue, esophagus,
stomach, duodenum,
jejunum, Ileum, colon,
rectum, liver, kidney,
stomach
None >1000, 100 Estonius et al., 1993;
Westerlund et al., 2007
ADH4 ADH7 Gastric mucosa Tongue, esophagus,
stomach
? 30, 1800 Westerlund et al., 2007
ADH5 ADH6 Liver, stomach ? ?. ?
ALDH (9 classes,
but 3 major in
rats)
Disulfiram IC50 of
acetaldehyde
metabolism (uM)
Quertemont, 2004
ALDH1 (RalDH) None Cytosolic (high Km
for acetaldehyde)
Tongue, esophagus,
stomach, duodenum,
jejunum, not detectible
in liver
? Human
0.15
Rat
0.10
Keung and Vallee, 1993;
Chen et al., 1996; Westerlund
et al., 2007; Koppaka et al.,
2012
ALDH2 None Mitochondria (Low
Km for
acetaldehyde)
Liver ? Human
1.45
Rat
>20
Keung and Vallee, 1993;
Koppaka et al., 2012
ALDH3 Constitutive,
xenobiotic inducible
GI tract ? ? Lindahl, 1992; Xie et al., 1996
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by irreversibly inhibiting the elimination of aldehydes formed by
ALDH (IC50 = 0.15 uM for ALDH1; IC50 = 1.45 uM for ALDH2)
(Koppaka et al., 2012) and therefore shifts the alcohol-aldehyde
equilibrium toward hydroxides (Brien et al., 1978; Cederbaum,
2012). Without ADH/ALDH to further metabolize hydroxyl
metabolites, a buildup of these could be compensated by reduced
production by CYPs, possibly due to mechanism-based inhibition
(Polasek et al., 2010). However, a potential zolpidem/disulfiram
interaction has not been studied. We therefore hypothesized that
sexual dimorphism in the expression of ADH and ALDH in
males and females is responsible for the observed sex differences
in zolpidem exposure, and that disulfiram treatment would
therefore have similar effects as castration via bypass of gastric
ADH/ALDH metabolism. The preclinical pilot study described
here details the PK analysis of zolpidem in Sprague–Dawley rats
in order to provide a preliminary understanding of the observed
clinical differences in zolpidem PK and pharmacodynamics (PD)
between males and females.
MATERIALS AND METHODS
Materials
Zolpidem free base (≥98% purity by HPLC) was purchased
from Sigma–Aldrich (St. Louis, MO, USA) through the NIH
Pharmacy. Zolpidem phenyl 4-carboxylic acid (ZPCA), ZCA, and
[H2]6-zolpidem (D6-zolpidem) were purchased from Toronto
Research Chemicals (Toronto, ON, Canada). Stock solutions
were prepared in DMSO (Sigma–Aldrich) that was subsequently
diluted in a 1% sucrose (aq) solution for oral gavage. Male and
female Sprague–Dawley rats were obtained from Charles River
Labs (Germantown, MD, USA). Disulfiram was purchased from
Sigma–Aldrich (St. Louis, MO, USA) as European Pharmacopeia
grade reference standard and was formulated for intraperitoneal
injection in a 1% suspension of carboxy methylcellulose (CMC),
purchased from Sigma–Aldrich (St. Louis, MO, USA), as
previously described (Sharkawi, 1980).
Study Design
Rats were separated into 5 treatment groups, each receiving
2.6 mg/kg zolpidem: (1) Group 1: uncastrated males receiving
CMC vehicle control (MC); (2) Group 2: uncastrated males
receiving disulfiram (MD); (3) Group 3: females receiving
disulfiram (FD); (4) Group 4: females receiving CMC vehicle
control (FC); and (5) Group 5: castrated males receiving
CMC vehicle control (cMC). Disulfiram was administered
intraperitoneally at a dose of 100 mg/kg approximately 16 h
before the middle of each zolpidem time point in order to
ensure Aldh inhibition was maximal (Gessner and Gessner,
1992). For example, rats corresponding to the 8 h time point were
administered disulfiram 12 h prior to zolpidem administration
(mid-point of the 8-h time is 4 h, thus 12 h prior to dose is 16 h)
whereas rats corresponding to the 1 h time point were treated
15.5 h prior to zolpidem administration. All rats were given food
and water ad libidum. Zolpidem was administered as an oral
gavage (volume 2 mL) at a dose of 2.6 mg/kg as had been used
previously (Garrigou-Gadenne et al., 1989). Male rats in Group 5
(cMC) were castrated according to an NIH Animal Care and Use
Committee (ACUC) approved procedure (Dulisch, 1976). Briefly,
castration surgeries were preformed through the abdominal wall.
To initiate and maintain the plane of anesthesia, 2.5% vaporized
isoflurane was inhaled with a 1.5 L/min flow rate. Excision of
the entire testicle and epididymis was accomplished by suturing
spermatic vessels and vas deferens closed. The peritoneum was
closed with 4–0 absorbable sutures and the outer abdominal skin
with surgical clips. Marcaine drops were used as a nerve block
and buprenorphine as an analgesic. During recovery, animals
were kept warm and watched until able to walk. They were
then returned to their cages and per protocol, were checked
every day after surgery for 5 days. After 10 days, surgical clips
were removed. All castrated males were treated with zolpidem
14 days after castration since serum testosterone concentrations
approach levels observed in females after that time, and a
previous work demonstrated Adh/Aldh differences in rats that
were only castrated for 7 days (Aasmoe and Aarbakke, 1999;
Christoffersen et al., 2006). All animal care and maintenance was
in accordance with NIH ACUC guidelines.
PK Sampling and Sample Bioanalysis
To examine the PK profile of zolpidem following oral gavage,
blood samples were collected in heparinized tubes via cardiac
puncture, and immediately placed on ice. Carbon dioxide
asphyxiation was conducted to ensure euthanasia and brains were
then harvested from each rat. Samples (plasma and whole brain)
were obtained at 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, and
8 h post gavage. Each time point was performed in three rats
within each group (seven time points in triplicate = 21 rats
per group). Immediately after collection, blood samples were
centrifuged for 5 min at 1200 × g. The plasma supernatant
was then immediately transferred to a cryovial and stored at
−80◦C until the time of bioanalysis. Brains were snap-frozen and
stored until needed, when they were thawed and homogenized
for bioanalysis. Plasma and brain concentrations of zolpidem
and its two major carboxylic acid metabolites ZPCA and ZCA
were quantitatively measured using a validated HPLC with
tandem mass spectrometric detection (HPLC-MS/MS) method
with a calibration range of 0.5–1,000 ug/L (ng/mL). Briefly,
100 uL of rat plasma was spiked with 2[H]6-zolpidem (internal
standard), acetonitrile was then added to precipitate proteins.
The acetonitrile extract was dried and the residue reconstituted.
Zolpidem, ZPCA, and ZCA had chromatographic retention times
of 4.8min, 3.6min, and 4.1 min, respectively; the deuterated
internal standard (2[H]6-zolpidem) eluted at the same time as
unlabeled zolpidem The assay was validated per FDA guidelines,
with accuracy and precision of calibration standards and quality
control standards less than 15% (Food and Drug Administration
[FDA], 2015).
Non-compartmental Analysis
A naïve-pooled, sparse non-compartmental (model-indepen-
dent) approach was used to calculate plasma and brain PK
parameters of zolpidem and the two metabolites, treating all data
as originating in one “average” rat, using Phoenix WinNonlin
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v6.4 (Certara Pharsight Corporation, Cary, NC, USA). Any
plasma or brain concentration measured below the LLOQ
(0.5 ug/L) was excluded from analyses. The maximum plasma
concentration (CMAX) and time to CMAX (TMAX) were recorded
as the mean (n = 3 per group) of observed values; the area
under the plasma concentration vs. time curve (AUCLAST)
was calculated using the linear trapezoidal rule as a linear
combination of the mean concentration values using observable
times up to 8 h. The standard error (SE) of the average CMAX
value in each treatment group was calculated as the sample
standard error of the concentration values at the observed
TMAX. The SE of the mean AUCLAST estimate from destructive
sampling was calculated according to the method of Nedelman
and Jia (1998). Bailer’s method Z-tests were used to calculate
the statistical differences in AUC between groups of rats using
Microsoft Excel R© (Bailer, 1988). Graphs were prepared using
GraphPad Prism, v6.01 (GraphPad Software, San Diego, CA,
USA) as well as all statistical analyses (except Bailer’s), where a
two-sided p < 0.05 was considered to be statistically significant.
Statistical Considerations
Comparisons between PK parameters (except AUC, which
was calculated with Bailer’s analysis) were conducted with
the Student’s t-test. Several comparisons were conducted with
only n = 3 rats in each group; therefore, individual PK
parameters have low power to detect differences between rats
and comparisons of such data will be reported as the mean and
95% CI.
RESULTS
Comparison of Zolpidem PK by Sex and
Castration Status
The concentration-time profiles for zolpidem, ZPCA and ZCA
from each treatment group are depicted in Figure 1. There was
relatively low response variability at most time points, however,
eight individual data points (i.e., individual samples from eight
rats) were excluded from analyses either due to noted errors in
gavage or blood draw technique (7/8), or the resulting plasma
concentration from bioanalysis being approximately 10 SDs
above the mean (1/8). The PK of zolpidem in males and females
treated with vehicle (1% CMC) were compared to demonstrate
the existence of sexual dimorphism in zolpidem clearance our
animal model. Consistent with human studies (Greenblatt et al.,
2000, 2014a), female rats had a 1.7-fold higher CMAX than males
(112 [36.4–188] vs. 68.1 [0.94–135] ug/L; Figure 2A) and a 2.3-
fold higher zolpidem AUCLAST (538 [419–657] vs. 232 [172-291]
h∗ug/L; Figure 2B). We therefore proposed that the gonadal
testosterone secretion was, in part, responsible for this sex effect,
and that this PK sex difference was likely related to differences in
Adh/Aldh expression rather than Cyp3a.
FIGURE 1 | Zolpidem plasma concentration vs. time profiles in (A) Group 1: uncastrated males + vehicle (1% CMC, i.p.), (B) Group 2: uncastrated
males + disulfiram (suspended in 1% CMC, i.p.), (C) Group 5: castrated males + vehicle, (D) Group 4: females + vehicle, and (E) Group 3:
females + disulfiram. Zolpidem (open squares), the major metabolite zolpidem phenyl 4-carboxylic acid (red circles), and the minor metabolite zolpidem
6-carboxylic acid (ZCA) (blue triangles) were measured in rat plasma at varying time points post oral gavage of 2.6 mg/kg either with the ADH/ALDH inhibitor
disulfiram, or its vehicle (CMC).
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FIGURE 2 | Zolpidem plasma (A) Cmax and (B) AUClast by sex and castration status, and (C) Cmax and (D) AUClast by sex and disulfiram status. Data
are represented by bar graphs depicting the mean ± the standard error of the mean (SEM), and p-values were determined by Bailer’s Z-test.
To test this latter hypothesis, zolpidem PK from castrated male
rats were compared to uncastrated male rats. Castrated males had
1.5-fold higher zolpidem AUCLAST (340 [215–464] h∗ug/L) and
1.6-fold higher CMAX (109 [21.1–197] ug/L) that was remarkably
similar to females (Figures 2A,B) and occurred at a much earlier
time point (TMAX = 15 min) than uncastrated males and females
(TMAX = 60 min). Plasma exposure was also greater at 15 and
30 min (AUC0−15 min or AUC0−30 min, fold change≥1.9), further
suggesting that castrated male rats were exposed to greater levels
of zolpidem earlier than uncastrated males or females. Castration
also induced a longer half-life (5.9 h vs. 3.3 h) compared to
uncastrated males. Nevertheless, castration appeared to affect first
pass metabolism more than other PK parameters, and the early
rise in plasma concentration (i.e., AUC0−30 min and CMAX) was
solely responsible for the greater overall AUCLAST observed in
castrated males vs. uncastrated males.
Comparison of Zolpidem PK with or
without Disulfiram
We next determined the effect of Adh/Aldh inhibition on
zolpidem metabolism by disulfiram, a potent ALDH inhibitor.
Disulfiram pretreatment resulted in very rapid absorption of
zolpidem (TMAX = 5min) with a CMAX that was 1.9-fold higher
in males (128 [86.6–168] ug/L), and only slightly higher in
females (145 [−1.29–291] ug/L; Figure 2C). This result was
not unexpected as male rats have been shown to express more
gastric Adh, which would be susceptible to greater inhibition
than females (see Table 1). Within each sex receiving disulfiram,
zolpidem AUC unexpectedly decreased (Figure 2D). This
observation suggests that the effect of disulfiram on zolpidem
metabolism may be dependent on the differential expression of
the Adh/Aldh isoenzyme along the GI tract.
Comparison of Zolpidem Plasma and
Brain Pharmacokinetics
Brain concentrations of zolpidem strikingly paralleled the plasma
profile over time, consistent with a previous report (Figure 3)
(Garrigou-Gadenne et al., 1989). Consequently, active drug
penetrates into the brain earlier (i.e., faster TMAX; 5 min vs.
1 h in males; 15 min vs. 30 min in females), and is more
rapidly removed from the brain in the presence of disulfiram
causing lower zolpidem brain AUCLAST in females (185 [145–
225] vs. 286 [211–361] h∗ng/g) and males (107 [70.3–143] vs.
165 [86.2–244] h∗ng/g; Figure 4). Females also had higher brain
AUC (286.1 [211–361] vs. 165 [86.2–244] h∗ng/g) and CMAX
(104 [−40.7–249] vs. 64.5 [−38.5–167] ng/g; Figure 4) than
males. However, brain zolpidem PK in castrated and uncastrated
males were similar for CMAX and AUC. Brain tissue exposure to
ZPCA was limited, and no brain samples had measureable ZCA
concentrations.
DISCUSSION
A sparse non-compartmental analysis demonstrated that a
2.6 mg/kg dose of zolpidem provided a CMAX (68.1 ug/L), TMAX
(1 h) and half-life (3.3 h) in uncastrated male rats (MC) that
were within reported ranges for healthy human adults given a
5 mg oral dose (Table 2) (Food and Drug Administration [FDA],
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FIGURE 3 | Zolpidem plasma and brain concentration vs. time profiles in (A) Group 1: uncastrated males + vehicle (1% CMC, i.p.), (B) Group 2:
uncastrated males + disulfiram (suspended in 1% CMC, i.p.), (C) Group 5: castrated males + vehicle, (D) Group 4: females + vehicle, and (E) Group 3:
females + disulfiram. Plasma concentrations (open squares) and brain concentrations (red squares) of zolpidem were measured in rats at varying time points post
oral gavage of 2.6 mg/kg either with the ADH/ALDH inhibitor disulfiram, or its vehicle (CMC).
FIGURE 4 | Zolpidem brain (A) Cmax and (B) AUClast by sex and castration status, and (C) Cmax and (D) AUClast by sex and disulfiram status. Data are
represented by bar graphs depicting the mean ± the standard error of the mean (SEM), and p-values were determined by Bailer’s Z-test.
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TABLE 2 | Pharmacokinetic (PK) Parameter Summary for Zolpidem, ZPCA, and ZCA in each Group.
Parameter HL Tmax Cmax SE_Cmax AUCall SE_AUCall
Units h h ng/mL ng/mL h∗ng/mL h∗ng/mL
Zolpidem
Males 3.26 1 68.1 15.61 231.82 25.15
Males+disulfiram 2.89 0.083 127.5 9.5 141.69 12.94
Females+disulfiram 2.76 0.083 145 34 302.8 23.97
Females 8.39 1 112.35 17.65 537.77 50.36
Castrated Males 5.96 0.25 109.07 20.44 339.72 52.6
Zolpidem Phenyl 4-Carboxylic Acid
Males 3.17 1 101.7 44.18 257.38 37.28
Males+disulfiram 3.54 0.083 123 5 278.2 20.94
Females+disulfiram 2.62 0.25 162.63 40.22 324.83 25.87
Females 4.22 0.5 88.25 32.75 352.1 47.29
Castrated males 6.16 1 105.77 45.07 316.84 55.49
Zolpidem 6-Carboxylic Acid
Males 6.43 1 2.13 0.97 9.17 1.12
Males+disulfiram 9.2 0.083 2.52 0.455 8.69 0.062
Females+disulfiram 4.12 1 3.64 0.66 13.48 0.84
Females 6.38 3 1.74 0.164 10.31 0.591
Castrated males 6.27 2 1.65 0.176 6.92 0.432
2008; Guo et al., 2014). Human adult CMAX, TMAX, and half-
life ranged between 30 and 113 ug/L, 0.79–1.61 h, and 1.4–4.5 h,
respectively, (Food and Drug Administration [FDA], 2008; Guo
et al., 2014; Stockmann et al., 2014). Zolpidem AUCLAST values
in MC rats (Mean [95%CI]: 232 [172–291] h∗ug/L) matched well
with a previous report in healthy human adults (234 h∗ug/L)
(Vlase et al., 2011), but rats demonstrated a faster apparent CL/F
(9 L/h/kg vs. 0.66 L/h/kg) (Olubodun et al., 2003) than humans.
Zolpidem phenyl 4-carboxylic acid was the predominant
metabolite formed through the Cyp3a→ Adh→ Aldh pathway,
with a metabolic ratio (metabolite:parent) for CMAX (1.39) and
AUC (1.25) that was 47-fold and 27-fold greater than that of ZCA
(0.029 and 0.045, respectively). This is consistent with an in vitro
study that demonstrated ZPCA and ZCA account for 72–86% and
10%, respectively, of urinary metabolites (Gillet, 1991; Pichard
et al., 1995).
Numerous studies demonstrate that zolpidem PD effects are
related to plasma concentrations (Visser et al., 2003; Verster
et al., 2014), that females have higher plasma concentrations
than males (Greenblatt et al., 2014a), and metabolism by CYP3A
does not explain this effect since females have similar or
higher CYP3A activity than males (Wolbold et al., 2003). The
present data suggest that sex differences in zolpidem PK are
partly a function of increased absorption, which is most likely
caused by previously observed sexual differences in Adh/Aldh
expression in the GI tract (Estonius et al., 1993; Aasmoe and
Aarbakke, 1999; Westerlund et al., 2007). These enzymes are
known to be even more sexually dimorphic in humans than
in rats (fourfold vs. twofold) (Aasmoe and Aarbakke, 1999)
(Parlesak et al., 2002), but this is the first study to address how
Adh/Aldh variability affects zolpidem PK between sexes. It was
previously demonstrated that female rats have greater activity of
hepatic Adh than male rats (21.5 vs. 12.0 nmol/NADH/min/mg
protein), suggesting testosterone reduces hepatic Adh expression,
and therefore activity (Aasmoe and Aarbakke, 1999). This was
confirmed when castrated male rats showed similar hepatic Adh
specific activity to female rats (17.5 vs. 21.5 nmol/NADH/min/mg
protein). The opposite was true for gastric Adh, where female
and castrated male rats had lower gastric Adh specific activity
(11.0 and 12.9 nmol/NADH/min/mg protein, respectively) vs.
uncastrated male rats (20.5 nmol/NADH/min/mg protein) for
ethanol (Aasmoe and Aarbakke, 1999). Therefore, female and
castrated male rats with lower testosterone levels exhibited
greater hepatic, but lower gastric, Adh activity, which manifested
as less gastric metabolism (i.e., faster absorption rate, earlier
TMAX, higher CMAX) and greater hepatic Adh/Aldh metabolism
(i.e., more metabolite exposure). Consistent with these findings,
our data showed female rats have an approximate 1.7-fold
higher CMAX and castrated males having an approximate 1.5-
fold higher CMAX, and earlier TMAX than uncastrated males.
This suggests that gonadal testosterone secretion promotes
gastric drug metabolism thereby acting as a barrier to drug
bioavailability.
Further confirming that Adh/Aldh is responsible for sex
differences in zolpidem absorption, disulfiram also caused both
increased absorption rate (earlier TMAX, higher CMAX) and
counterintuitively a more rapid elimination rate, which is
manifested as a lower AUC in disulfiram-treated rats regardless
of sex. Thus, zolpidem appears to be metabolized in part by
gastric Adh/Aldh that reduces drug absorption into the systemic
circulation. Similar to observations with ethanol (Ciccone and
Holdcroft, 1999), a reduction in metabolism through this
pathway would be expected to cause both a greater rate of
absorption and increased bioavailability (Crabb et al., 1987;
Greenblatt et al., 2013, 2014a). Although the specifics of in vivo
Adh/Aldh metabolism have not been elucidated, we suggest that
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this is the most plausible explanation for the higher CMAX, earlier
TMAX, and yet lower AUC in disulfiram-treated rats.
While previous clinical studies have reported lower systemic
clearance (calculated as Dose/AUC) in females vs. males (2.7–
2.8 vs. 3.9–4.0 ml/min/kg, p < 0.06), consistent with females
having greater overall exposure, the mechanisms behind the
increased exposure are not fully understood (Greenblatt et al.,
2000, 2014a). It is plausible that a major source of the increased
exposure in females is due to their greater absorption due to
lower gastric Adh/Adh, as was observed for ethanol (Frezza
et al., 1990). A lower “clearance” in females is not necessarily
a factor of impaired metabolism/elimination, but rather due
to increased exposure, likely from increased absorption/oral
bioavailability from lower gastric ADH expression. Although the
sublingual route demonstrated comparable fold-change increases
in exposure (1.4-fold) in females vs. males compared to the
enteral route (immediate release), this observed sex difference in
exposure, and therefore clearance, in sublingual route is possibly
due to ADH expression in the oral and gastric mucosa (Moreno
et al., 1994; Hedberg et al., 2000). Thus, the sublingual route could
still be affected by gender differences in ADH expression.
Future studies should compare zolpidem PK following IV
and oral administration to study the specific contribution of
gastric and liver metabolism to overall zolpidem disposition
and should clarify which specific Adh/Aldh isozymes are
responsible for zolpidem metabolism. Such studies should also
investigate whether first-pass metabolism is also related to sex
differences in the pharmacological effects and side effects if
zolpidem. Additionally, zolpidem (more likely the CYP-mediated
hydroxyl metabolites) has been demonstrated to be a weak
(Ki = 122 uM) mechanism-based inhibitor (both time- and
concentration-dependent) for CYP3A4, but due to the relatively
high Ki value, was deemed to be unlikely to cause clinical drug
interactions (Polasek et al., 2010). Previous studies have only
focused on pharmacodynamics interactions in the brain and not
differences in ADH expression affecting bioavailability (Devaud
and Morrow, 1994; Devaud et al., 1995; Tuk et al., 2002).
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